Nothing Special   »   [go: up one dir, main page]

WO2001090358A2 - Proteines de recepteurs de mammiferes, reactifs et procedes apparentes - Google Patents

Proteines de recepteurs de mammiferes, reactifs et procedes apparentes Download PDF

Info

Publication number
WO2001090358A2
WO2001090358A2 PCT/US2001/016767 US0116767W WO0190358A2 WO 2001090358 A2 WO2001090358 A2 WO 2001090358A2 US 0116767 W US0116767 W US 0116767W WO 0190358 A2 WO0190358 A2 WO 0190358A2
Authority
WO
WIPO (PCT)
Prior art keywords
leu
pro
ser
ala
val
Prior art date
Application number
PCT/US2001/016767
Other languages
English (en)
Other versions
WO2001090358A3 (fr
Inventor
Daniel M. Gorman
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to JP2001587152A priority Critical patent/JP2003534013A/ja
Priority to MXPA02011617A priority patent/MXPA02011617A/es
Priority to AU2001274920A priority patent/AU2001274920A1/en
Priority to CA002410083A priority patent/CA2410083A1/fr
Priority to EP01941579A priority patent/EP1303604A2/fr
Publication of WO2001090358A2 publication Critical patent/WO2001090358A2/fr
Publication of WO2001090358A3 publication Critical patent/WO2001090358A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to compositions and methods for affecting mammalian physiology, including immune system function. In particular, it provides methods to regulate development and/or the immune system. Diagnostic and therapeutic uses of these materials are also disclosed.
  • BACKGROUND OF THE INVENTION refers generally to techniques of integrating genetic information from a donor source into vectors for subsequent processing, such as through introduction into a host, whereby the transferred genetic information is copied and/or expressed in the new environment.
  • the genetic information exists in the form of complementary DNA (cDNA) derived from messenger RNA (mRNA) coding for a desired protein product.
  • cDNA complementary DNA
  • mRNA messenger RNA
  • the carrier is frequently a plasmid having the capacity to incorporate cDNA for later replication in a host and, in some cases, actually to control expression of the cDNA and thereby direct synthesis of the encoded product in the host. See, e.g., Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.) vols. 1-3, CSH Press, NY.
  • the immune system of vertebrates consists of a number of organs and several different cell types.
  • Two major cell types include the myeloid and lymphoid lineages.
  • lymphoid cell lineage are B cells, which were originally characterized as differentiating in fetal liver or adult bone marrow, and T cells, which were originally characterized as differentiating in the thymus. See, e.g., Paul (ed. 1998) Fundamental
  • Lymphokines apparently mediate cellular activities in a variety of ways. They have been shown to support the proliferation, growth, and/or differentiation of cells, e.g., pluripotential hematopoietic stem cells, into vast numbers of progenitors comprising diverse cellular lineages which make up a complex immune system. Proper and balanced interactions between the cellular components are necessary for a healthy immune response. The different cellular lineages often respond in a different manner when lymphokines are administered in conj unction with other agents.
  • B-cells which can produce and secrete immunoglobulins (proteins with the capability of recognizing and binding to foreign matter to effect its removal), and T-cells of various subsets that secrete lymphokines and induce or suppress the B-cells and various other cells (including other T-cells) making up the immune network.
  • T-cells of various subsets that secrete lymphokines and induce or suppress the B-cells and various other cells (including other T-cells) making up the immune network.
  • the discovery and characterization of specific cytokines and their receptors will contribute to the development of therapies for a broad range of degenerative or other conditions which affect the immune system, hematopoietic cells, as well as other cell types.
  • the present invention provides new receptors for ligands exhibiting similarity to cytokine like compositions and related compounds, and methods for their use.
  • the present invention is directed to novel receptors related to cytokine receptors, e.g., primate, cytokine receptor like molecular structures, designated DNAX Cytokine Receptor Subunits (DCRS), and their biological activities.
  • DCRS DNAX Cytokine Receptor Subunits
  • Primate e.g, human, and rodent, e.g., mouse, embodiments of the various subunits are provided.
  • It includes nucleic acids coding for the polypeptides themselves and methods for their production and use.
  • the nucleic acids of the invention are characterized, in part, by their homology to cloned complementary DNA (cDNA) sequences enclosed herein.
  • the present invention provides a composition of matter selected from: a substantially pure or recombinant polypeptide comprising at least three distinct nonoverlapping segments of at least four amino acids identical to segments of SEQ ID NO: 2, 5, 8, 11, 23, or 26; a substantially pure or recombinant polypeptide comprising at least three distinct nonoverlapping segments of at least four amino acids identical to segments of SEQ ID NO: 14; a substantially pure or recombinant polypeptide comprising at least two distinct nonoverlapping segments of at least five amino acids identical to segments of SEQ ID NO: 14; a natural sequence DCRS8 comprising mature SEQ ID NO: 14; a fusion polypeptide comprising DCRS 8 sequence; a substantially pure or recombinant polypeptide comprising at least three distinct nonoverlapping segments of at least four amino acids identical to segments of SEQ ID NO: 17 or 20; a substantially pure or recombinant polypeptide comprising at least two distinct nonoverlapping segments of at least five amino acids identical to segments of SEQ ID NO: 17 or 20; a natural sequence DCRS
  • the distinct nonoverlapping segments of identity include: one of at least eight amino acids; one of at least four amino acids and a second of at least five amino acids; at least three segments of at least four, five, and six amino acids, or one of at least twelve amino acids.
  • the: polypeptide comprises a mature sequence of Tables 1, 2, 3, 4, or 5; is an unglycosylated form of DCRS8 or DCRS9; is from a primate, such as a human; comprises at least seventeen amino acids of SEQ ID NO: 14 or 17; exhibits at least four nonoverlapping segments of at least seven amino acids of SEQ ID NO: 14 or 17; is a natural allelic variant of DCRS8 or DCRS9; has a length at least about 30 amino acids; exhibits at least two non-overlapping epitopes which are specific for a primate DCRS8 or DCRS9; is glycosylated; has a molecular weight of at least 30 kD with natural glycosylation; is a synthetic polypeptide; is attached to a solid substrate; is conjugated to another chemical moiety; is a 5-fold or less substitution from natural sequence; or is a deletion or insertion variant from a natural sequence.
  • the invention further embraces a composition
  • a composition comprising: a substantially pure DCRS 8 or DCRS9 and another cytokine receptor family member; a sterile DCRS 8 or DCRS9 polypeptide; the DCRS8 or DCRS9 polypeptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration.
  • Additional embodiments include a polypeptide comprising: mature protein sequence of Tables 1, 2, 3, 4, or 5; a detection or purification tag, including a FLAG, His6, or Ig sequence; or sequence of another cytokine receptor protein.
  • Kit embodiments include ones comprising a described polypeptide, and: a compartment comprising the protein or polypeptide; or instructions for use or disposal of reagents in the kit.
  • the invention also provides methods of producing an antigen: antibody complex, comprising contacting under appropriate conditions a primate DCRS8 or DCRS9 polypeptide with a described antibody, thereby allowing the complex to form.
  • Preferred methods include ones wherein: the complex is purified from other cytokine receptors; the complex is purified from other antibody; the contacting is with a sample comprising an interferon; the contacting allows quantitative detection of the antigen; the contacting is with a sample comprising the antibody; or the contacting allows quantitative detection of the antibody.
  • compositions include those comprising: a sterile binding compound, as described, or the binding compound and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration.
  • Nucleic acid compositions include an isolated or recombinant nucleic acid encoding a desribed polypeptide wherein the: DCRS8 or DCRS9 is from a human; or the nucleic acid: encodes an antigenic peptide sequence of Table 3 or 4; encodes a plurality of antigenic peptide sequences of Table 3 or 4; exhibits identity over at least thirteen nucleotides to a natural cDNA encoding the segment; is an expression vector; further comprises an origin of replication; is from a natural source; comprises a detectable label; comprises synthetic nucleotide sequence; is less than 6 kb, preferably less than 3 kb; is from a primate; comprises a natural full length coding sequence; is a hybridization probe for a gene encoding the DCRS8 or DCRS9; or is a PCR primer, PCR product, or mutagenesis primer.
  • a cell or tissue comprising such a recombinant nucleic acid, e.g., where the cell is: a prokaryotic cell; a eukaryotic cell; a bacterial cell; a yeast cell; an insect cell; a mammalian cell; a mouse cell; a primate cell; or a human cell.
  • Kit embodiments include those comprising a described nucleic acid and: a compartment comprising the nucleic acid; a compartment further comprising a primate DCRS 8 or DCRS9 polypeptide; or instructions for use or disposal of reagents in the kit.
  • Other nucleic acids provided include ones which: hybridize under wash conditions of 30 minutes at 30° C and less than 2M salt to the coding portion of SEQ ID NO: 13 or
  • nucleic acids where: the wash conditions are: at 45° C and/or 500 mM salt; at 55° C and/or 150 mM salt; or the stretch is at least 55 or 75 nucleotides.
  • methods of modulating physiology or development of a cell or tissue culture cells comprising contacting the cell with an agonist or antagonist of a mammalian DCRS8 or DCRS9.
  • the cell is transformed with a nucleic acid encoding the DCRS8 or DCRS9 and another cytokine receptor subunit.
  • Proteins, Peptides A fragments, sequence, immunogens, antigens
  • the present invention provides the amino acid sequence and DNA sequence of mammalian, herein primate, cytokine receptor-like subunit molecules, these designated DNAX Cytokine Receptor Subunits 6 (DCRS6), 7 (DCRS7), 8 (DCRS8), 9 (DCRS9), and 10 (DCRS 10) having particular defined properties, both structural and biological.
  • DCRS6 DNAX Cytokine Receptor Subunits 6
  • DCRS7 DNAX Cytokine Receptor Subunits 6
  • DCRS8 DCRS8
  • 9 DCRS9
  • DCRS 10 10 having particular defined properties, both structural and biological.
  • Various cDNAs encoding these molecules were obtained from primate, e.g., human, and/or rodent, e.g., mouse, cDNA sequence libraries. Other primate or other mammalian counterparts would also be desired.
  • Nucleotide (SEQ ID NO: 1) and corresponding amino acid sequence (SEQ ID NO: 2) of a primate, e.g., human, DCRS6 coding segment is shown in Table 1 along with reverse translation (SEQ ID NO: 3).
  • Rodent, e.g., mouse, counterpart sequences are provided, e.g., SEQ ID NO: 4-6.
  • SEQ ID NO: 8 of a primate, e.g., human, DCRS7 coding segment is shown in Table 2 along with reverse translation (SEQ ID NO: 9).
  • Rodent, e.g., mouse, counterpart sequences are provided, e.g., SEQ ID NO: 10-12.
  • Nucleotide (SEQ ID NO: 13) and corresponding amino acid sequence (SEQ ID NO: 14) of a primate, e.g., human, DCRS8 coding segment is shown in Table 3 along with reverse translation (SEQ ID NO: 15).
  • Nucleotide (SEQ ID NO: 16) and corresponding amino acid sequence (SEQ ID NO: 17) of a primate, e.g., human, DCRS9 coding segment is shown in Table 4 along with reverse translation (SEQ ID NO: 18).
  • Rodent, e.g., mouse, counterpart sequences are provided, e.g., SEQ ID NO: 19-21.
  • Nucleotide (SEQ ID NO: 22) and corresponding amino acid sequence (SEQ ID NO: 23) of a primate, e.g., human, DCRS 10 coding segment is shown in Table 5 along with reverse translation (SEQ ID NO: 24).
  • Rodent, e.g., mouse, counterpart sequences are provided, e.g., SEQ ID NO: 26-27.
  • Table 1 Nucleotide and polypeptide sequences of DNAX Cytokine Receptor Subunit like embodiments (DCRS6). Primate, e.g., human, embodiment (see SEQ ID NO: 1 and 2).
  • Predicted signal sequence indicated but may vary by a few positions and depending upon cell type. gcg atg teg etc gtg ctg eta age ctg gee gcg ctg tgc agg age gee 48 Met Ser Leu Val Leu Leu Ser Leu Ala Ala Leu Cys Arg Ser Ala
  • MSLVLLSLAALCRSAVPREPTVQCGSETGPSPE MLQHDLIPGDLRDLRVEPVTTSVATGDYSILMNVSWVL RADASIRLLKATKICVTGKSWFQSYSCVRCNYTEAFQTQTRPSGGKWTFSYIGFPVELNTVYFIGAH IPHA M EDGPSMSV FTSPGCLDHIMKYKKKCVKAGSL DPNITACKK EETVEV FTTTPLGNRYMALIQHSTI IGFSQVFEPHQKKQTRASWIPVTGDSEGATVQLTPYFPTCGSDCIRHKGTWLCPQTGVPFPLDNNKSKPG GWLPLLLLSLLVAT VLVAGIYLM RHERIKKTSFSTTTLLPPIKVLWYPSEICFHHTICYFTEFLQNHCR SEVILEK QKKKIAEMGPVQ LATQKKAADKWFLLSNDV SVCDGTCGKSEGSPSENSQDLFPLAFWLFCS DLRSQIHLHKY WYFREID
  • Reverse translation ofprimate e.g., human, DCRS6 (SEQ ID NO: 3): atgwsnytng tnytnytnws nytngcngcn ytntgymgnw sngcngtncc nmgngarccn 60 acngtncart gyggn snga racnggnccn snccngart ggatgytnca rcaygayytn 120 athccnggng ayytnmgnga yytnmgngtn garccngtna cnacnwsngt ngcnacnggn 180 gaytaywsna thytnatgaa ygtnwsntgg gtnytnmgng cngaygcnws nathmgnytn 240 ytnaargcna c
  • Rodent e.g., mouse embodiment (see SEQ ID NO: 4 and 5).
  • rodent e.g., mouse, DCRS6 (SEQ ID NO: 6) : gayttywsnw sncaracnca yytncayaar tayytngarg tntayytngg nggngcngay 60 ytnaarggng aytayaaygc nytnwsngtn tgyccncart aycayytnat gaargaygcn 120 acngcnttyc ayacngaryt nytnaargcn acncarwsna tgwsngtnaa raarmgnwsn 180 cargcntgyc aygaywsntg ywsnccnytn 210
  • DCRS7 DNAX Cytokine Receptor Subunit like embodiments
  • Primate e.g., human, embodiment (see SEQ ID NO: 7 and 8).
  • Predicted signal sequence indicated, but may vary by a few positions and depending upon cell type.
  • primate e.g., human, DCRS7 (SEQ ID NO: 9): atgccngtnc cntggttyyt nytnwsnytn gcnytnggnm gnwsncartg gathytnwsn 60 ytngarmgny tngtnggncc ncargaygcn acncaytgyw snccnggnyt nwsntgymgn 120 ytntgggayw sngayathyt ntgyytnccn ggngayathg tnccngcncc nggnccngtn 180 ytngcnccna cncayytnca racngarytn gtnytnmgnt gycaraarga racngaytgy 240 gayy
  • Predicted signal sequence indicated may vary by a fewpositions and depending upon cell type.
  • ccaaatcgaa agcacgggag ctgatactgg gcctggagtc caggctcact ggagtgggga 60 agcatggctg gagaggaatt ctagcccttg ctctctccca gggacacggg gctgattgtc 120 agcaggggcg aggggtctgc cccccttgg gggggcagga cggggcctca ggcctgggtg 180 ctgtccggca cctggaag atg cct gtg tec tgg ttc ctg ctg tec ttg gca 231
  • Reverse translation ofrodent e.g., mouse, DCRS7 (SEQ ID NO: 12): atgccngtnw sntggttyyt nytnwsnytn gcnytnggnm gnaayccngt ngtngtnwsn 60 ytngarmgny tnatggarcc ncargayacn gcnmgntgyw snytnggnyt nwsntgycay 120 ytntgggayg gngaygtnyt ntgyytnccn ggnwsnytnc arwsngcncc nggnccngtn 180 ytngtnccna cnmgnytnca racngarytn gtnytnmgnt gyccncaraa racngaytgy 240
  • DCRS 8 DNAX Cytokine Receptor Subunit like embodiments
  • Primate e.g., human, embodiment (see SEQ ID NO: 13 and 14).
  • Predicted signal sequence indicated, but may vary by a few positions and depending upon cell type.
  • ctg gtg gat gac act aac aca aca aga aaa gtg atg cat tat gcc tta 927 Leu Val Asp Asp Thr Asn Thr Thr Arg Lys Val Met His Tyr Ala Leu 255 260 265 270 aag cca gtg cac tec ccg tgg gcc ggg ccc ate aga gcc gtg gcc ate 975 Lys Pro Val His Ser Pro Trp Ala Gly Pro He Arg Ala Val Ala He 275 280 285 aca gtg cca ctg gta gtc ata tcg gca ttc gcg acg etc ttc act gtg 1023 Thr Val Pro Leu Val Val He Ser Ala Phe Ala Thr Leu Phe Thr Val
  • Table 4 Nucleotide and polypeptide sequences of DNAX Cytokine Receptor Subunit like embodiments (DCRS9). Primate, e.g., human, embodiment (see SEQ ID NO: 16 and 17).
  • Predicted signal sequence indicated, but may vary by a few positions and depending upon cell type. atg ggg age tec aga ctg gca gcc ctg etc ctg cct etc etc ata 48 Met Gly Ser Ser Arg Leu Ala Ala Leu Leu Leu Pro Leu Leu Leu He
  • Trp Pro Glu Ala Tyr Gly Ser Asp Phe Trp Lys Ser Val His Phe Thr 250 255 260 265 gac tac age cag cac act cag atg gtc atg gcc ctg aca etc cgc tgc 912
  • Reverse translation ofprimate e.g., human, DCRS9 (SEQ ID NO: 18): atgggnwsnw snmgnytngc ngcnytnytn ytnccnytny tnytnathgt nathgayytn 60 wsngaywsng cnggnathgg nttymgncay ytnccncayt ggaayacnmg ntgyccnytn 120 gcnwsncaya cngargtnyt nccnathwsn ytngcngcnc cnggnggncc nwsnwsnccn 180 carwsnytng gngtntgyga rwsnggnacn gtnccngcng tntgygcnws nathtgytg
  • Rodent e.g., mouse, embodiment (see SEQ ID NO: 19 and 20). Predicted signal sequence indicated, but may vary by a few positions and depending upon cell type. cagctccggg ccaggccctg ctgccctctt gcagacagga aagacatggt ctctgcgccc 60 tgatcctaca gaagctc atg ggg age ccc aga ctg gca gcc ttg etc ctg 110
  • Reverse translation ofrodent e.g., mouse, DCRS9 (SEQ ID NO: 21): atgggnwsnc cnmgnytngc ngcnytnytn ytnwsnytnc cnytnytnyt nathggnytn 60 gcngtnwsng cnmgngtngc ntgyccntgy ytnmgnwsnt ggacnwsnca ytgyytnytn 120 gcntaymgng tngayaarmg nttygcnggn ytncartggg gntggttycc nytnytngtn 180 mgnaarwsna arwsnccncc naarttygar gaytaytggm gncaymgnac nccngcnwsn 240
  • Reverse translation ofprimate e.g., human, DCRS10 (SEQ ID NO: 24): atgaaymgnw snathccngt ngargtngay garwsngarc cntayccnws ncarytnytn 60 aarccnathc cngartayws nccngargar garwsngarc cnccngcncc naayathmgn 120 aayatggcnc cnaaywsnyt nwsngcnccn acnatgytnc ayaaywsnws nggngaytty 180 wsncargcnc aywsnacnyt naarytngcn aaycaycarm gnccngtnws nmgncargtn 240 acntgyytnm
  • Rodent, e.g., mouse, embodiment (see SEQ ID NO: 25 and 26).
  • cag gac etc cct ggg cct ctg agg tec agg gaa ttg cca cct cag ttt 48 Gin Asp Leu Pro Gly Pro Leu Arg Ser Arg Glu Leu Pro Pro Gin Phe 1 5 10 15 gaa ctt gag agg tat cca atg aac gcc cag ctg ctg ccg ccc cat cct 96 Glu Leu Glu Arg Tyr Pro Met Asn Ala Gin Leu Leu Pro Pro His Pro 20 25 30 tec cca cag gcc cca tgg aac tgt cag tac tac tgc ccc gga ggg ccc 144 Ser Pro Gin Ala Pro Trp Asn Cys Gin Tyr Tyr Cys Pro Gly Gly Pro 35 40 45 tac cac
  • the IL- 17R_Hu (SEQ ID NO: 28) is GenBank AAB99730.1(U58917), gi
  • DCRS10 R DKTVMIIVAISPKYKQDVE GAESQLDED-EHGL HTKYIHRM-MQIEFIK
  • DCRS10_Mu R DKTVMIIVAISPKYKQDVE GAESQLDED-EHGL HTKYIHRM-MQIEFIS
  • DCRS6 Ce DSIDSRNNSK THSTDSGVSSLSS NS-- Table 6 shows comparison of the available sequences of primate, rodent, and various other receptors. Various conserved residues are aligned and indicated. The structually homologous cytoplasmic domains most likely signal through pathways like IL-17, e.g., through NFkB. Similar to IL-1 signalling, it is likely that these receptors are invloved in innate immunity and/or development.
  • DCRS shall be used to describe a protein comprising amino acid sequences shown in Tables 1-5, respectively. In many cases, a substantial fragment thereof will be functionally or structurally equivalent, including, e.g., an extracellular or intracellular domain.
  • the invention also includes a protein variation of the respective DCRS allele whose sequence is provided, e.g., a mutein or soluble extracellular construct. Typically, such agonists or antagonists will exhibit less than about 10% sequence differences, and thus will often have between 1 and 11 substitutions, e.g., 2-, 3-, 5-, 7-fold, and others. It also encompasses allelic and other variants, e.g., natural polymorphic, of the protein described.
  • the term shall also be used herein to refer to related naturally occurring forms, e.g., alleles, polymorphic variants, and metabolic variants of the mammalian protein.
  • Preferred forms of the receptor complexes will bind the appropriate ligand with an affinity and selectivity appropriate for a ligand-receptor interaction.
  • This invention also encompasses combinations of proteins or peptides having substantial amino acid sequence identity with an amino acid sequence in Tables 1-5. It will include sequence variants with relatively few residue substitutions, e.g., preferably less than about 3-5.
  • a substantial polypeptide "fragment”, or “segment” is a stretch of amino acid residues of at least about 8 amino acids, generally at least 10 amino acids, more generally at least 12 amino acids, often at least 14 amino acids, more often at least 16 amino acids, typically at least 18 amino acids, more typically at least 20 amino acids, usually at least 22 amino acids, more usually at least 24 amino acids, preferably at least 26 amino acids, more preferably at least 28 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids.
  • fragments may exhibit functional properties of the intact subunits, e.g., the extracellular domain of the transmembrane receptor may retain the ligand binding features, and may be used to prepare a soluble receptor-like complex.
  • Amino acid sequence homology, or sequence identity is determined by optimizing residue matches. In some comparisons, gaps may be introduces, as required. See, e.g., Needleham, et al., (1970) J. Mol. Biol. 48:443-453: Sankoff, et al., (1983) chapter one in Time Warps. String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison. Addison- Wesley, Reading, MA; and software packages from
  • Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
  • Homologous amino acid sequences are intended to include natural allelic and interspecies variations in the cytokine sequence. Typical homologous proteins or peptides will have from 50-100% homology (if gaps can be introduced), to 60-100% homology (if conservative substitutions are included) with an amino acid sequence segment of, e.g., Table 3 or 4.
  • Homology measures will be at least about 70%, generally at least 76%, more generally at least 81%, often at least 85%, more often at least 88%, typically at least 90%, more typically at least 92%, usually at least 94%, more usually at least 95%, preferably at least 96%, and more preferably at least 97%, and in particularly preferred embodiments, at least 98% or more.
  • the degree of homology will vary with the length of the compared segments.
  • Homologous proteins or peptides, such as the allelic variants, will share most biological activities with the embodiments described in Tables 1-5.
  • biological activity is used to describe, without limitation, effects on inflammatory responses, innate immunity, and/or morphogenic development by cytokine-like ligands.
  • these receptors should mediate phosphatase or phosphorylase activities, which activities are easily measured by standard procedures. See, e.g., Hardie, et al. (eds. 1995) The Protein Kinase FactBook vols. I and II, Academic Press, San Diego, CA; Hanks, et al. (1991) Meth. Enzvmol. 200:38-62; Hunter, et al. (1992) Cell 70:375-388; Lewin (1990) CeU 61:743-752; Pines, et al. (1991) Cold Spring Harbor Svmp. Quant. Biol. 56:449-463; and Parker, et al. (1993) Nature
  • the receptors, or portions thereof, may be useful as phosphate labeling enzymes to label general or specific substrates.
  • the subunits may also be functional immunogens to elicit recognizing antibodies, or antigens capable of binding antibodies.
  • the terms ligand, agonist, antagonist, and analog of, e.g., a DCRS8 or DCRS9, include molecules that modulate the characteristic cellular responses to cytokine ligand proteins, as well as molecules possessing the more standard structural binding competition features of ligand-receptor interactions, e.g., where the receptor is a natural receptor or an antibody. The cellular responses likely are typically mediated through receptor tyrosine kinase pathways.
  • a ligand is a molecule which serves either as a natural ligand to which said receptor, or an analog thereof, binds, or a molecule which is a functional analog of the natural ligand.
  • the functional analog may be a ligand with structural modifications, or may be a wholly unrelated molecule which has a molecular shape which interacts with the appropriate ligand binding determinants.
  • the ligands may serve as agonists or antagonists, see, e.g., Goodman, et al. (eds. 1990) Goodman & Gilman's: The Pharmacological Bases of Therapeutics. Pergamon Press, New York.
  • Rational drug design may also be based upon structural studies of the molecular shapes of a receptor or antibody and other effectors or ligands. See, e.g., Herz, et al. (1997) J. Recept. Signal Transduct. Res. 17:671-776; and Chaiken, et al. (1996) Trends Biotechnol. 14:369-375. Effectors may be other proteins which mediate other functions in response to ligand binding, or other proteins which normally interact with the receptor.
  • One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York, which is hereby incorporated herein by reference.
  • the cytokine receptor-like proteins will have a number of different biological activities, e.g., modulating cell proliferation, or in phosphate metabolism, being added to or removed from specific substrates, typically proteins. Such will generally result in modulation of an inflammatory function, other innate immunity response, or a morphological effect.
  • the subunit will probably have a specific low affinity binding to the ligand.
  • the DCRS8 and DCRS9 have characteristic motifs of receptors signaling through the JAK pathway. See, e.g., Uile, et al. (1997) Stem Cells 15(suppl. 1):105-111;
  • Substrates may be identified, or conditions for enzymatic activity may be assayed by standard methods, e.g., as described in Hardie, et al. (eds. 1995) The Protein Kinase FactBook vols. I and II, Academic Press, San Diego, CA; Hanks, et al. (1991) Meth. Enzvmol. 200:38-62; Hunter, et al. (1992) Cell 70:375- 388; Lewin (1990) Cell 61:743-752; Pines, et al. (1991) Cold Spring Harbor Svmp. Quant. Biol. 56:449-463; and Parker, et al. (1993) Nature 363:736-738.
  • the receptor subunits may combine to form functional complexes, e.g., which may be useful for binding ligand or preparing antibodies. These will have substantial diagnostic uses, including detection or quantitation.
  • This invention contemplates use of isolated nucleic acid or fragments, e.g., which encode these or closely related proteins, or fragments thereof, e.g., to encode a corresponding polypeptide, preferably one which is biologically active.
  • this invention covers isolated or recombinant DNAs which encode combinations of such proteins or polypeptides having characteristic sequences, e.g., of the DCRSs.
  • the nucleic acid is capable of hybridizing, under appropriate conditions, with a nucleic acid sequence segment shown in Tables 1-5, but preferably not with a corresponding segment of other receptors described in Table 6.
  • Said biologically active protein or polypeptide can be a full length protein, or fragment, and will typically have a segment of amino acid sequence highly homologous, e.g., exhibiting significant stretches of identity, to one shown in Tables 1-5. Further, this invention covers the use of isolated or recombinant nucleic acid, or fragments thereof, which encode proteins having fragments which are equivalent to the DCRS 8 or DCRS9 proteins.
  • the isolated nucleic acids can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others from the natural gene. Combinations, as described, are also provided.
  • an “isolated” nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially pure, e.g., separated from other components which naturally accompany a native sequence, such as ribosomes, polymerases, and flanking genomic sequences from the originating species.
  • the term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates, which are thereby distinguishable from naturally occurring compositions, and chemically synthesized analogs or analogs biologically synthesized by heterologous systems.
  • a substantially pure molecule includes isolated forms of the molecule, either completely or substantially pure.
  • An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain heterogeneity, preferably minor. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.
  • a "recombinant" nucleic acid is typically defined either by its method of production or its structure.
  • the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence.
  • this intervention involves in vitro manipulation, although under certain circumstances it may involve more classical animal breeding techniques.
  • it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants as found in their natural state.
  • products made by transforming cells with an unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process.
  • Such a process is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a restriction enzyme sequence recognition site.
  • the process is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms, e.g., encoding a fusion protein.
  • Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design.
  • site specific targets e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design.
  • a similar concept is intended for a recombinant, e.g., fusion, polypeptide. This will include a dimeric repeat.
  • synthetic nucleic acids which, by genetic code redundancy, encode equivalent polypeptides to fragments of DCRSs and fusions of sequences from various different related molecules, e.g., other cytokine receptor family members.
  • a "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides, generally at least 21 nucleotides, more generally at least 25 nucleotides, ordinarily at least 30 nucleotides, more ordinarily at least 35 nucleotides, often at least 39 nucleotides, more often at least 45 nucleotides, typically at least 50 nucleotides, more typically at least 55 nucleotides, usually at least 60 nucleotides, more usually at least 66 nucleotides, preferably at least 72 nucleotides, more preferably at least 79 nucleotides, and in particularly preferred embodiments will be at least 85 or more nucleotides.
  • fragments of different genetic sequences can be compared to one another over appropriate length stretches, particularly defined segments such as the domains described below.
  • a nucleic acid which codes for the DCRS8 or DCRS9 will be particularly useful to identify genes, mRNA, and cDNA species which code for itself or closely related proteins, as well as DNAs which code for polymorphic, allelic, or other genetic variants, e.g., from different individuals or related species.
  • Preferred probes for such screens are those regions of the interleukin which are conserved between different polymorphic variants or which contain nucleotides which lack specificity, and will preferably be full length or nearly so. In other situations, polymorphic variant specific sequences will be more useful.
  • This invention further covers recombinant nucleic acid molecules and fragments having a nucleic acid sequence identical to or highly homologous to the isolated DNA set forth herein.
  • sequences will often be operably linked to DNA segments which control transcription, translation, and DNA replication. These additional segments typically assist in expression of the desired nucleic acid segment.
  • nucleic acid sequences when compared to one another, e.g., DCRS8 sequences, exhibit significant similarity.
  • the standards for homology in nucleic acids are either measures for homology generally used in the art by sequence comparison or based upon hybridization conditions. Comparative hybridization conditions are described in greater detail below.
  • Substantial identity in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 60% of the nucleotides, generally at least 66%, ordinarily at least 71%, often at least 76%, more often at least 80%, usually at least 84%, more usually at least 88%, typically at least 9 /o, more typically at least about 93%, preferably at least about 95%), more preferably at least about 96 to 98% or more, and in particular embodiments, as high at about 99% or more of the nucleotides, including, e.g., segments encoding structural domains such as the segments described below.
  • the length of homology comparison may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, generally at least about 20 nucleotides, ordinarily at least about 24 nucleotides, usually at least about 28 nucleotides, typically at least about 32 nucleotides, more typically at least about 40 nucleotides, preferably at least about 50 nucleotides, and more preferably at least about 75 to 100 or more nucleotides. This includes, e.g., 125, 150, 175, 200, 225, 246, 273, and other lengths.
  • Stringent conditions in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters typically controlled in hybridization reactions.
  • Stringent temperature conditions will usually include temperatures in excess of about 30 C, more usually in excess of about 37 C, typically in excess of about 45 C, more typically in excess of about 55 C, preferably in excess of about 65 C, and more preferably in excess of about 70 C.
  • Stringent salt conditions will ordinarily be less than about 500 mM, usually less than about 400 mM, more usually less than about 300 mM, typically less than about 200 mM, preferably less than about 100 mM, and more preferably less than about 80 mM, even down to less than about 20 mM.
  • the isolated DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode this protein or its derivatives. These modified sequences can be used to produce mutant proteins (muteins) or to enhance the expression of variant species. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms.
  • mutant DCRS8-like derivatives include predetermined or site-specific mutations of the protein or its fragments, including silent mutations using genetic code degeneracy.
  • “Mutant DCRS8” as used herein encompasses a polypeptide otherwise falling within the homology definition of the DCRS 8 as set forth above, but having an amino acid sequence which differs from that of other cytokine receptor-like proteins as found in nature, whether by way of deletion, substitution, or insertion.
  • site specific mutant DCRS 8 encompasses a protein having substantial sequence identity with a protein of Table 3, and typically shares most of the biological activities or effects of the forms disclosed herein. Although site specific mutation sites are predetermined, mutants need not be site specific.
  • Mammalian DCRS 8 mutagenesis can be achieved by making amino acid insertions or deletions in the gene, coupled with expression. Substitutions, deletions, insertions, or many combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy- terminal fusions. Random mutagenesis can be conducted at a target codon and the expressed mammalian DCRS mutants can then be screened for the desired activity, providing some aspect of a structure-activity relationship. Methods for making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by Ml 3 primer mutagenesis. See also Sambrook, et al. (1989) and Ausubel, et al. (1987 and periodic Supplements).
  • the mutations in the DNA normally should not place coding sequences out of reading frames and preferably will not create complementary regions that could hybridize to produce secondary mRNA structure such as loops or hairpins.
  • PCR Polymerase chain reaction
  • Certain embodiments of the invention are directed to combination compositions comprising the receptor or ligand sequences described.
  • functional portions of the sequences may be joined to encode fusion proteins.
  • variants of the described sequences may be substituted.
  • the present invention encompasses primate DCRS6-10, e.g., whose sequences are disclosed in Tables 1-5, and described above. Allelic and other variants are also contemplated, including, e.g., fusion proteins combining portions of such sequences with others, including, e.g., epitope tags and functional domains.
  • the present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these primate or rodent proteins.
  • a heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner.
  • the fusion product of, e.g., a DCRS8 with another cytokine receptor is a continuous protein molecule having sequences fused in a typical peptide linkage, typically made as a single translation product and exhibiting properties, e.g., sequence or antigenicity, derived from each source peptide.
  • a similar concept applies to heterologous nucleic acid sequences. Combinations of various designated proteins into complexes are also provided.
  • new constructs may be made from combimng similar functional or structural domains from other related proteins, e.g., cytokine receptors or Toll-like receptors, including species variants.
  • ligand-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science 243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem. 263 : 15985-15992, each of which is incorporated herein by reference.
  • new chimeric polypeptides exhibiting new combinations of specificities will result from the functional linkage of receptor-binding specificities.
  • a fusion protein may include a targeting domain which may serve to provide sequestering of the fusion protein to a particular subcellular organelle.
  • Candidate fusion partners and sequences can be selected from various sequence data bases, e.g., GenBank, c/o IntelliGenetics, Mountain View, CA; and BCG, University of Wisconsin Biotechnology Computing Group, Madison, WI, which are each inco ⁇ orated herein by reference.
  • GenBank GenBank
  • c/o IntelliGenetics Mountain View, CA
  • BCG University of Wisconsin Biotechnology Computing Group
  • Variant forms of the proteins may be substituted in the described combinations.
  • the present invention particularly provides muteins which bind cytokine-like ligands, and/or which are affected in signal transduction.
  • Structural alignment of human DCRSs with other members of the cytokine receptor family show conserved features/residues. See Table 6. Alignment of the human DCRS 8 sequence with other members of the cytokine receptor family indicates various structural and functionally shared features. See also, Bazan, et al. (1996) Nature 379:591; Lodi, et al. (1994) Science 263:1762-1766; Sayle and Milner-White (1995) TIBS 20:374-376; and Gronenberg, et al. (1991) Protein Engineering 4:263-269.
  • “Derivatives" of the primate DCRS8 include amino acid sequence mutants, glycosylation variants, metabolic derivatives and covalent or aggregative conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of f nctionalities to groups which are found in the DCRS 8 amino acid side chains or at the N- or C- termini, e.g., by means which are well known in the art.
  • These derivatives can include, without limitation, aliphatic esters or amides of the carboxyl terminus, or of residues containing carboxyl side chains, O-acyl derivatives of hydroxyl group-containing residues, and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g., lysine or arginine.
  • Acyl groups are selected from the group of alkyl-moieties, including C3 to C18 normal alkyl, thereby forming alkanoyl aroyl species.
  • glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. Particularly preferred means for accomplishing this are by exposing the polypeptide to glycosylating enzymes derived from cells which normally provide such processing, e.g., mammalian glycosylation enzymes. Deglycosylation enzymes are also contemplated. Also embraced are versions of the same primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.
  • a major group of derivatives are covalent conjugates of the receptors or fragments thereof with other proteins of polypeptides. These derivatives can be synthesized in recombinant culture such as N- or C-terminal fusions or by the use of agents known in the art for their usefulness in cross-linking proteins through reactive side groups. Preferred derivatization sites with cross-linking agents are at free amino groups, carbohydrate moieties, and cysteine residues.
  • Fusion polypeptides between the receptors and other homologous or heterologous proteins are also provided.
  • Homologous polypeptides may be fusions between different receptors, resulting in, for instance, a hybrid protein exhibiting binding specificity for multiple different cytokine ligands, or a receptor which may have broadened or weakened specificity of substrate effect.
  • heterologous fusions may be constructed which would exhibit a combination of properties or activities of the derivative proteins.
  • Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of a receptor, e.g., a ligand-binding segment, so that the presence or location of a desired ligand may be easily determined.
  • GST glutathione-S-transferase
  • bacterial ⁇ -galactosidase bacterial ⁇ -galactosidase
  • trpE Protein A
  • Protein A ⁇ -lactamase
  • alpha amylase alpha amylase
  • alcohol dehydrogenase and yeast alpha mating factor.
  • Godowski et al. (1988) Science 241:812-816. Labeled proteins will often be substituted in the described combinations of proteins.
  • polypeptides may also have amino acid residues which have been chemically modified by phosphorylation, sulfonation, biotinylation, or the addition or removal of other moieties, particularly those which have molecular shapes similar to phosphate groups.
  • the modifications will be useful labeling reagents, or serve as purification targets, e.g., affinity ligands.
  • Fusion proteins will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, for example, in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), Vols. 1-3, Cold Spring Harbor Laboratory, and Ausubel, et al. (eds. 1987 and periodic supplements) Current Protocols in Molecular Biology. Greene/Wiley, New York, which are each incorporated herein by reference. Techniques for synthesis of polypeptides are described, for example, in Merrifield (1963)
  • Such covalent or aggregative derivatives are useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of a receptor or other binding molecule, e.g., an antibody.
  • a cytokine ligand can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated Sepharose, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of a cytokine receptor, antibodies, or other similar molecules.
  • the ligand can also be labeled with a detectable group, for example radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates, or conjugated to another fluorescent moiety for use in diagnostic assays.
  • a combination e.g., including a DCRS8, of this invention can be used as an immunogen for the production of antisera or antibodies specific, e.g., capable of distinguishing between other cytokine receptor family members, for the combinations described.
  • the complexes can be used to screen monoclonal antibodies or antigen- binding fragments prepared by immunization with various forms of impure preparations containing the protein.
  • the term "antibodies” also encompasses antigen binding fragments of natural antibodies, e.g., Fab, Fab2, Fv, etc.
  • the purified DCRS 8 can also be used as a reagent to detect antibodies generated in response to the presence of elevated levels of expression, or immunological disorders which lead to antibody production to the endogenous receptor.
  • DCRS 8 fragments may also serve as immunogens to produce the antibodies of the present invention, as described immediately below.
  • this invention contemplates antibodies having binding affinity to or being raised against the amino acid sequences shown in Tables 1-5, fragments thereof, or various homologous peptides.
  • this invention contemplates antibodies having binding affinity to, or having been raised against, specific fragments which are predicted to be, or actually are, exposed at the exterior protein surface of the native DCRS8 or DCRS9. Complexes of combinations of proteins will also be useful, and antibody preparations thereto can be made.
  • the blocking of physiological response to the receptor ligands may result from the inhibition of binding of the ligand to the receptor, likely through competitive inhibition.
  • in vitro assays of the present invention will often use antibodies or antigen binding segments of these antibodies, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either ligand binding region mutations and modifications, or other mutations and modifications, e.g., which affect signaling or enzymatic function.
  • This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to the receptor complexes or fragments compete with a test compound for binding to a ligand or other antibody.
  • the neutralizing antibodies or fragments can be used to detect the presence of a polypeptide which shares one or more binding sites to a receptor and can also be used to occupy binding sites on a receptor that might otherwise bind a ligand.
  • DNA which encodes the protein or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or by screening genomic libraries prepared from a wide variety of cell lines or tissue samples. Natural sequences can be isolated using standard methods and the sequences provided herein, e.g., in Tables 1-5. Other species counte ⁇ arts can be identified by hybridization techniques, or by various PCR techniques, combined with or by searching in sequence databases, e.g., GenBank.
  • This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length receptor or fragments which can in turn, for example, be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified ligand binding or kinase/phosphatase domains; and for structure/function studies.
  • Variants or fragments can be expressed in host cells that are transformed or transfected with appropriate expression vectors. These molecules can be substantially free of protein or cellular contaminants, other than those derived from the recombinant host, and therefore are particularly useful in pharmaceutical compositions when combined with a pharmaceutically acceptable carrier and/or diluent.
  • the protein, or portions thereof may be expressed as fusions with other proteins. Combinations of the described proteins, or nucleic acids encoding them, are particularly interesting.
  • Expression vectors are typically self-replicating DNA or RNA constructs containing the desired receptor gene or its fragments, usually operably linked to suitable genetic control elements that are recognized in a suitable host cell. These control elements are capable of effecting expression within a suitable host.
  • the multiple genes may be coordinately expressed, and may be on a polycistronic message. The specific type of control elements necessary to effect expression will depend upon the eventual host cell used.
  • the genetic control elements can include a prokaryotic promoter system or a eukaryotic promoter expression control system, and typically include a transcriptional promoter, an optional operator to control the onset of transcription, transcription enhancers to elevate the level of mRNA expression, a sequence that encodes a suitable ribosome binding site, and sequences that terminate transcription and translation.
  • Expression vectors also usually contain an origin of replication that allows the vector to replicate independently of the host cell.
  • the vectors of this invention include those which contain DNA which encodes a combination of proteins, as described, or a biologically active equivalent polypeptide.
  • the DNA can be under the control of a viral promoter and can encode a selection marker.
  • This invention further contemplates use of such expression vectors which are capable of expressing eukaryotic cDNAs coding for such proteins in a prokaryotic or eukaryotic host, where the vector is compatible with the host and where the eukaryotic cDNAs are inserted into the vector such that growth of the host containing the vector expresses the cDNAs in question.
  • expression vectors are designed for stable replication in their host cells or for amplification to greatly increase the total number of copies of the desirable gene per cell.
  • Vectors as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host.
  • Expression vectors are specialized vectors which contain genetic control elements that effect expression of operably linked genes. Plasmids are the most commonly used form of vector but all other forms of vectors which serve an equivalent function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual. Elsevier, N.Y., and Rodriguez, et al. (eds. 1988) Vectors: A Survey of Molecular Cloning Vectors and Their Uses.
  • Transformed cells are cells, preferably mammalian, that have been transformed or transfected with vectors constructed using recombinant DNA techniques.
  • Transformed host cells usually express the desired proteins, but for pu ⁇ oses of cloning, amplifying, and manipulating its DNA, do not need to express the subject proteins.
  • This invention further contemplates culturing transformed cells in a nutrient medium, thus permitting the proteins to accumulate.
  • the proteins can be recovered, either from the culture or, in certain instances, from the culture medium.
  • nucleic sequences are operably linked when they are functionally related to each other.
  • DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide.
  • a promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide;
  • a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation.
  • operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression.
  • Suitable host cells include prokaryotes, lower eukaryotes, and higher eukaryotes.
  • Prokaryotes include both gram negative and gram positive organisms, e.g., E. coli and R. subtilis.
  • Lower eukaryotes include yeasts, e.g., S. cerevisiae and Pichia. and species of the genus Dictvostelium.
  • Higher eukaryotes include established tissue culture cell lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents.
  • Prokaryotic host- vector systems include a wide variety of vectors for many different species. As used herein, E. coli and its vectors will be used generically to include equivalent vectors used in other prokaryotes.
  • a representative vector for amplifying DNA is pBR322 or many of its derivatives.
  • Vectors that can be used to express the receptor or its fragments include, but are not limited to, such vectors as those containing the lac promoter (pUC-series); t ⁇ promoter (pBR322-frp); Ipp promoter (the pIN-series); lambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540). See Brosius, et al. (1988) "Expression Vectors Employing Lambda-, t ⁇ -, lac-, and Ipp-derived Promoters", in Vectors: A Survey of Molecular Cloning Vectors and
  • Lower eukaryotes e.g., yeasts and Dictvostelium. may be transformed with DCRS 8 sequence containing vectors.
  • the most common lower eukaryotic host is the baker's yeast, Saccharomyces cerevisiae. It will be used to generically represent lower eukaryotes although a number of other strains and species are also available.
  • Yeast vectors typically consist of a replication origin (unless of the integrating type), a selection gene, a promoter, DNA encoding the receptor or its fragments, and sequences for translation termination, polyadenylation, and transcription termination.
  • Suitable expression vectors for yeast include such constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters or such inducible promoters as the alcohol dehydrogenase 2 promoter or metallothionine promoter.
  • Suitable vectors include derivatives of the following types: self-replicating low copy number (such as the YRp-series), self-replicating high copy number (such as the YEp-series); integrating types (such as the Yip-series), or mini-chromosomes (such as the YCp-series).
  • Higher eukaryotic tissue culture cells are normally the preferred host cells for expression of the functionally active interleukin or receptor proteins. In principle, many higher eukaryotic tissue culture cell lines are workable, e.g., insect baculovirus expression systems, whether from an invertebrate or vertebrate source. However, mammalian cells are preferred. Transformation or transfection and propagation of such cells has become a routine procedure.
  • Examples of useful cell lines include HeLa cells, Chinese hamster ovary (CHO) cell lines, baby rat kidney (BRK) cell lines, insect cell lines, bird cell lines, and monkey (COS) cell lines.
  • Expression vectors for such cell lines usually include an origin of replication, a promoter, a translation initiation site, RNA splice sites (if genomic DNA is used), a polyadenylation site, and a transcription termination site. These vectors also usually contain a selection gene or amplification gene.
  • Suitable expression vectors may be plasmids, viruses, or retroviruses carrying promoters derived, e.g., from such sources as from adenovirus, SV40, parvoviruses, vaccinia virus, or cytomegalovirus.
  • Suitable expression vectors include pCDNAl; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMClneo PolyA, see Thomas, et al. (1987) CeU 51 :503-512; and a baculovirus vector such as pAC 373 or pAC 610.
  • an open reading frame usually encodes a polypeptide that consists of a mature or secreted product covalently linked at its N-terminus to a signal peptide.
  • the signal peptide is cleaved prior to secretion of the mature, or active, polypeptide.
  • the cleavage site can be predicted with a high degree of accuracy from empirical rules, e.g., von-Heijne (1986) Nucleic Acids Research 14:4683-
  • polypeptides it will often be desired to express these polypeptides in a system which provides a specific or defined glycosylation pattern.
  • the usual pattern will be that provided naturally by the expression system.
  • the pattern will be modifiable by exposing the polypeptide, e.g., an unglycosylated form, to appropriate glycosylating proteins introduced into a heterologous expression system.
  • the receptor gene may be co-transformed with one or more genes encoding mammalian or other glycosylating enzymes.
  • certain mammalian glycosylation patterns will be achievable in prokaryote or other cells. Expression in prokaryote cells will typically lead to unglycosylated forms of protein.
  • the source of DCRS 8 can be a eukaryotic or prokaryotic host expressing recombinant DCRS8, such as is described above.
  • the source can also be a cell line, but other mammalian cell lines are also contemplated by this invention, with the preferred cell line being from the human species.
  • the primate DCRS8 or DCRS9, fragments, or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis. Pierce Chemical Co., Rockford, IL; Bodanszky and Bodanszky (1984)
  • an azide process for example, an acid chloride process, an acid anhydride process, a mixed anhydride process, an active ester process (for example, p-nitrophenyl ester, N-hydroxysuccinimide ester, or cyanomethyl ester), a carbodiimidazole process, an oxidative-reductive process, or a dicyclohexylcarbodiimide (DCCD)/additive process can be used.
  • an active ester process for example, p-nitrophenyl ester, N-hydroxysuccinimide ester, or cyanomethyl ester
  • DCCD dicyclohexylcarbodiimide
  • DCRS8 proteins, fragments, or derivatives are suitably prepared in accordance with the above processes as typically employed in peptide synthesis, generally either by a so-called stepwise process which comprises condensing an amino acid to the terminal amino acid, one by one in sequence, or by coupling peptide fragments to the terminal amino acid. Amino groups that are not being used in the coupling reaction typically must be protected to prevent coupling at an incorrect location.
  • the C-terminal amino acid is bound to an insoluble carrier or support through its carboxyl group.
  • the insoluble carrier is not particularly limited as long as it has a binding capability to a reactive carboxyl group.
  • examples of such insoluble carriers include halomethyl resins, such as chloromethyl resin or bromomethyl resin, hydroxymethyl resins, phenol resins, tert-alkyloxycarbonylhydrazidated resins, and the like.
  • An amino group-protected amino acid is bound in sequence through condensation of its activated carboxyl group and the reactive amino group of the previously formed peptide or chain, to synthesize the peptide step by step.
  • the peptide is split off from the insoluble carrier to produce the peptide.
  • This solid-phase approach is generally described by Merrifield, et al. (1963) in J. Am. Chem. Soc. 85:2149-2156, which is inco ⁇ orated herein by reference.
  • the prepared protein and fragments thereof can be isolated and purified from the reaction mixture by means of peptide separation, e.g., by extraction, precipitation, electrophoresis, various forms of chromatography, and the like.
  • the receptors of this invention can be obtained in varying degrees of purity depending upon desired uses. Purification can be accomplished by use of the protein purification techniques disclosed herein, see below, or by the use of the antibodies herein described in methods of immunoabsorbant affinity chromatography.
  • This immunoabsorbant affinity chromatography is carried out by first linking the antibodies to a solid support and then contacting the linked antibodies with solubilized lysates of appropriate cells, lysates of other cells expressing the receptor, or lysates or supernatants of cells producing the protein as a result of DNA techniques, see below.
  • the purified protein will be at least about 40% pure, ordinarily at least about 50%) pure, usually at least about 60% pure, typically at least about 70% pure, more typically at least about 80% pure, preferable at least about 90% pure and more preferably at least about 95% pure, and in particular embodiments, 97%-99% or more.
  • Purity will usually be on a weight basis, but can also be on a molar basis. Different assays will be applied as appropriate. Individual proteins may be purified and thereafter combined.
  • Antibodies can be raised to the various mammalian, e.g., primate DCRS8 or
  • DCRS9 proteins and fragments thereof both in naturally occurring native forms and in their recombinant forms, the difference being that antibodies to the active receptor are more likely to recognize epitopes which are only present in the native conformations.
  • Denatured antigen detection can also be useful in, e.g., Western analysis.
  • Anti-idiotypic antibodies are also contemplated, which would be useful as agonists or antagonists of a natural receptor or an antibody.
  • Antibodies, including binding fragments and single chain versions, against predetermined fragments of the protein can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins.
  • Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective protein, or screened for agonistic or antagonistic activity.
  • the antibodies, including antigen binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be potent antagonists that bind to the receptor and inhibit binding to ligand or inhibit the ability of the receptor to elicit a biological response, e.g., act on its substrate. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides to bind producing cells, or cells localized to the source of the interleukin. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker.
  • the antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they might bind to the receptor without inhibiting ligand or substrate binding. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying ligand. They may be used as reagents for Western blot analysis, or for immunoprecipitation or immunopurification of the respective protein. Likewise, nucleic acids and proteins may be immobilized to solid substrates for affinity purification or detection methods. The substrates may be, e.g., solid resin beads or sheets of plastic. Protein fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens.
  • Mammalian cytokine receptors and fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See (1969) Microbiology. Hoeber Medical Division, Ha ⁇ er and Row; Landsteiner (1962) Specificity of Serological Reactions. Dover Publications, New York; and Williams, et al.
  • a typical method involves hyperimmunization of an animal with an antigen. The blood of the animal is then collected shortly after the repeated immunizations and the gamma globulin is isolated.
  • monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc.
  • Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual. CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York; and particularly in Kohler and Milstein (1975) Nature
  • the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal.
  • labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.
  • recombinant or chimeric immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; or made in transgenic mice, see Mendez, et al. (1997) Nature Genetics 15: 146-
  • the antibodies of this invention can also be used for affinity chromatography in isolating the DCRS8 proteins or peptides.
  • Columns can be prepared where the antibodies are linked to a solid support, e.g., particles, such as agarose, Sephadex, or the like, where a cell lysate may be passed through the column, the column washed, followed by increasing concentrations of a mild denaturant, whereby the purified protein will be released.
  • the protein may be used to purify antibody. Appropriate cross abso ⁇ tions or depletions may be applied.
  • the antibodies may also be used to screen expression libraries for particular expression products. Usually the antibodies used in such a procedure will be labeled with a moiety allowing easy detection of presence of antigen by antibody binding.
  • Antibodies raised against a cytokine receptor will also be used to raise anti- idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the protein or cells which express the protein. They also will be useful as agonists or antagonists of the ligand, which may be competitive inhibitors or substitutes for naturally occurring ligands.
  • a cytokine receptor protein that specifically binds to or that is specifically immunoreactive with an antibody generated against a defined immunogen, such as an immunogen consisting of the amino acid sequence of SEQ ID NO: 14, is typically determined in an irnmunoassay.
  • the irnmunoassay typically uses a polyclonal antiserum which was raised, e.g., to a protein of SEQ ID NO: 14. This antiserum is selected to have low crossreactivity against other cytokine receptor family members, preferably from the same species, and any such crossreactivity is removed by immunoabso ⁇ tion prior to use in the irnmunoassay.
  • the protein e.g., of SEQ ID NO: 14 is isolated as described herein.
  • recombinant protein may be produced in a mammalian cell line.
  • An appropriate host e.g., an inbred strain of mice such as Balb/c, is immunized with the selected protein, typically using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see Harlow and Lane, supra).
  • a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used an immunogen.
  • Polyclonal sera are collected and titered against the immunogen protein in an irnmunoassay, e.g., a solid phase irnmunoassay with the immunogen immobilized on a solid support.
  • an irnmunoassay e.g., a solid phase irnmunoassay with the immunogen immobilized on a solid support.
  • Polyclonal antisera with a titer of 10 ⁇ or greater are selected and tested for their cross reactivity against other cytokine receptor family members using a competitive binding irnmunoassay such as the one described in Harlow and Lane, supra, at pages 570-
  • cytokine receptor family members are used in this determination.
  • These cytokine receptor family members can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein.
  • Immunoassays in the competitive binding format can be used for the crossreactivity determinations.
  • the protein of SEQ ID NO: 14 can be immobilized to a solid support. Proteins added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the other proteins. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabso ⁇ tion with the above-listed proteins.
  • the immunoabsorbed and pooled antisera are then used in a competitive binding irnmunoassay as described above to compare a second protein to the immunogen protein (e.g., the DCRS8 like protein of SEQ ID NO: 14).
  • the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% > of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than twice the amount of the protein of the selected protein or proteins that is required, then the second protein is said to specifically bind to an antibody generated to the immunogen.
  • these cytokine receptor proteins are members of a family of homologous proteins that comprise at least 9 so far identified members, 6 mammalian and 3 worm embodiments.
  • the term refers not only to the amino acid sequences disclosed herein, but also to other proteins that are allelic, non-allelic, or species variants.
  • the terms include nonnatural mutations introduced by deliberate mutation using conventional recombinant technology such as single site mutation, or by excising short sections of DNA encoding the respective proteins, or by substituting new amino acids, or adding new amino acids. Such minor alterations typically will substantially maintain the immunoidentity of the original molecule and/or its biological activity.
  • these alterations include proteins that are specifically immunoreactive with a designated naturally occurring DCRS 8 protein.
  • the biological properties of the altered proteins can be determined by expressing the protein in an appropriate cell line and measuring the appropriate effect, e.g., upon transfected lymphocytes. Particular protein modifications considered minor would include conservative substitution of amino acids with similar chemical properties, as described above for the cytokine receptor family as a whole. By aligning a protein optimally with the protein of the cytokine receptors and by using the conventional immunoassays described herein to determine immunoidentity, one can determine the protein compositions of the invention.
  • cytokine receptor like molecules of this invention are particularly useful in kits and assay methods. For example, these methods would also be applied to screening for binding activity, e.g., ligands for these proteins.
  • Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds per year. See, e.g., a BIOMEK automated workstation, Beckman Instruments, Palo Alto, California, and Fodor, et al. (1991) Science 251 :767-773, which is inco ⁇ orated herein by reference. The latter describes means for testing binding by a plurality of defined polymers synthesized on a solid substrate.
  • suitable assays to screen for a ligand or agonist/antagonist homologous proteins can be greatly facilitated by the availability of large amounts of purified, soluble cytokine receptors in an active state such as is provided by this invention.
  • Purified protein can be coated directly onto plates for use in the aforementioned ligand screening techniques.
  • non-neutralizing antibodies to these proteins can be used as capture antibodies to immobilize the respective receptor on the solid phase, useful, e.g., in diagnostic uses.
  • This invention also contemplates use of receptor subunit, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of the protein or its ligand.
  • antibodies against the molecules may be inco ⁇ orated into the kits and methods.
  • the kit will have a compartment containing, e.g., a DCRS8 peptide or gene segment or a reagent which recognizes one or the other.
  • recognition reagents in the case of peptide, would be a receptor or antibody, or in the case of a gene segment, would usually be a hybridization probe.
  • a preferred kit for determining the concentration of DCRS 8 in a sample would typically comprise a labeled compound, e.g., ligand or antibody, having known binding affinity for DCRS8, a source of DCRS8 (naturally occurring or recombinant) as a positive control, and a means for separating the bound from free labeled compound, e.g., a solid phase for immobilizing the DCRS 8 in the test sample.
  • a labeled compound e.g., ligand or antibody, having known binding affinity for DCRS8
  • a source of DCRS8 naturally occurring or recombinant
  • a means for separating the bound from free labeled compound e.g., a solid phase for immobilizing the DCRS 8 in the test sample.
  • Compartments containing reagents, and instructions will normally be provided.
  • Appropriate nucleic acid or protein containing kits are also provided.
  • Antibodies including antigen binding fragments, specific for mammalian DCRS8 or a peptide fragment, or receptor fragments are useful in diagnostic applications to detect the presence of elevated levels of ligand and/or its fragments. Diagnostic assays may be homogeneous (without a separation step between free reagent and antibody-antigen complex) or heterogeneous (with a separation step).
  • Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme irnmunoassay (EIA), enzyme-multiplied irnmunoassay technique (EMIT), substrate-labeled fluorescent irnmunoassay (SLFIA) and the like.
  • unlabeled antibodies can be employed by using a second antibody which is labeled and which recognizes the antibody to a cytokine receptor or to a particular fragment thereof.
  • a second antibody which is labeled and which recognizes the antibody to a cytokine receptor or to a particular fragment thereof.
  • Anti-idiotypic antibodies may have similar use to serve as agonists or antagonists of cytokine receptors. These should be useful as therapeutic reagents under appropriate circumstances.
  • the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay.
  • the protocol, and the label either labeled or unlabeled antibody, or labeled ligand is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like.
  • the kit will also contain instructions for proper use and disposal of the contents after use.
  • the kit has compartments for each useful reagent, and will contain instructions for proper use and disposal of reagents.
  • the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium having appropriate concentrations for performing the assay.
  • the aforementioned constituents of the diagnostic assays may be used without modification or may be modified in a variety of ways.
  • labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal.
  • a test compound, cytokine receptor, or antibodies thereto can be labeled either directly or indirectly.
  • Possibilities for direct labeling include label groups: radiolabels such as 125 ⁇ enzymes (U.S. Pat. No.
  • the cytokine receptor can be immobilized on various matrixes followed by washing. Suitable matrices include plastic such as an ELISA plate, filters, and beads. Methods of immobilizing the receptor to a matrix include, without limitation, direct adhesion to plastic, use of a capture antibody, chemical coupling, and biotin-avidin. The last step in this approach involves the precipitation of antibody/antigen complex by any of several methods including those utilizing, e.g., an organic solvent such as polyethylene glycol or a salt such as ammonium sulfate.
  • Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of an cytokine receptor. These sequences can be used as probes for detecting levels of the respective cytokine receptor in patients suspected of having an immunological disorder.
  • the preparation of both RNA and DNA nucleotide sequences, the labeling of the sequences, and the preferred size of the sequences has received ample description and discussion in the literature.
  • an oligonucleotide probe should have at least about 14 nucleotides, usually at least about 18 nucleotides, and the polynucleotide probes may be up to several kilobases.
  • Various labels may be employed, most commonly radionuclides, particularly 32p, However, other techniques may also be employed, such as using biotin modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed which can recognize specific duplexes, including DNA duplexes, RNA duplexes, DNA-RNA hybrid duplexes, or DNA-protein duplexes.
  • the antibodies in turn may be labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
  • probes to the novel RNA may be carried out in conventional techniques such as nucleic acid hybridization, plus and minus screening, recombinational probing, hybrid released translation (HRT), and hybrid arrested translation (HART).
  • Antisense nucleic acids which may be used to block protein expression, are also provided. See, e.g., Isis Pharmaceuticals, Sequitur, Inc., or Hybridon. This also includes amplification techniques such as polymerase chain reaction (PCR).
  • kits which also test for the qualitative or quantitative presence of other markers are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g., Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97.
  • Therapeutic Utility provides reagents with significant therapeutic value. See, e.g.,
  • cytokine receptors naturally occurring or recombinant
  • fragments thereof, mutein receptors, and antibodies should be useful in the treatment of conditions exhibiting abnormal expression of the receptors of their ligands.
  • Such abnormality will typically be manifested by immunological disorders, e.g., innate immunity, or developmentally.
  • this invention should provide therapeutic value in various diseases or disorders associated with abnormal expression or abnormal triggering of response to the ligand.
  • the IL-1 ligands have been suggested to be involved in mo ⁇ hologic development, e.g., dorso-ventral polarity determination, and immune responses, particularly the primitive innate responses. See, e.g., Sun, et al. (1991) Eur. J. Biochem. 196:247-254; and Hultmark (1994) Nature 367:116-117.
  • Recombinant cytokine receptors, muteins, agonist or antagonist antibodies thereto, or antibodies can be purified and then administered to a patient.
  • These reagents can be combined for therapeutic use with additional active ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, along with physiologically innocuous stabilizers and excipients.
  • additional active ingredients e.g., in conventional pharmaceutically acceptable carriers or diluents, along with physiologically innocuous stabilizers and excipients.
  • These combinations can be sterile, e.g., filtered, and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations.
  • This invention also contemplates use of antibodies or binding fragments thereof which are not complement binding.
  • Ligand screening using cytokine receptor or fragments thereof can be performed to identify molecules having binding affinity to the receptors. Subsequent biological assays can then be utilized to determine if a putative ligand can provide competitive binding, which can block intrinsic stimulating activity. Receptor fragments can be used as a blocker or antagonist in that it blocks the activity of ligand. Likewise, a compound having intrinsic stimulating activity can activate the receptor and is thus an agonist in that it simulates the activity of ligand, e.g., inducing signaling. This invention further contemplates the therapeutic use of antibodies to cytokine receptors as antagonists.
  • reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, reagent physiological life, pharmacological life, physiological state of the patient, and other medicants administered.
  • treatment dosages should be titrated to optimize safety and efficacy.
  • dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents.
  • Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage.
  • Various considerations are described, e.g., in Gihnan, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics. 8th Ed., Pergamon Press; and Remington's
  • compositions for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others.
  • Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck
  • dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about
  • Cytokine receptors, fragments thereof, and antibodies or its fragments, antagonists, and agonists may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration.
  • Therapeutic formulations may be administered in many conventional dosage formulations. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
  • Formulations comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof.
  • Each carrier must be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient.
  • Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by methods well known in the art of pharmacy. See, e.g., Gihnan, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics. 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences. 17th ed.
  • the therapy of this invention may be combined with or used in association with other therapeutic agents, particularly agonists or antagonists of other cytokine receptor family members.
  • DCRS8 Drug screening using DCRS8 or fragments thereof can be performed to identify compounds having binding affinity to the receptor subunit, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic stimulating activity and is therefore a blocker or antagonist in that it blocks the activity of the ligand. Likewise, a compound having intrinsic stimulating activity can activate the receptor and is thus an agonist in that it simulates the activity of a cytokine ligand. This invention further contemplates the therapeutic use of antibodies to the receptor as cytokine agonists or antagonists. Similarly, complexes comprising multiple proteins may be used to screen for ligands or reagents capable of recognizing the complex.
  • cytokine receptors comprise at least two subunits, which may be the same, or distinct.
  • the transmembrane receptor may bind to a complex comprising a cytokine-like ligand associated with another soluble protein serving, e.g., as a second receptor subunit.
  • One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing the DCRS8 in combination with another cytokine receptor subunit. Cells may be isolated which express a receptor in isolation from other functional receptors. Such cells, either in viable or fixed form, can be used for standard antibody/antigen or ligand/receptor binding assays. See also, Parce, et al. (1989) Science 246:243-247; and Owicki, et al. (1990) Proc. ⁇ at'l Acad.
  • This separation step could typically involve a procedure such as adhesion to filters followed by washing, adhesion to plastic followed by washing, or centrifugation of the cell membranes.
  • Viable cells could also be used to screen for the effects of drugs on cytokine mediated functions, e.g., second messenger levels, e.g., Ca "1 ⁇ " ; cell proliferation; inositol phosphate pool changes; and others.
  • Some detection methods allow for elimination of a separation step, e.g., a proximity sensitive detection system. Calcium sensitive dyes will be useful for detecting Ca ++ levels, with a fluorimeter or a fluorescence cell sorting apparatus.
  • DCRS 8 provides means to identify ligands, as described above. Such ligand should bind specifically to the respective receptor with reasonably high affinity.
  • Various constructs are made available which allow either labeling of the receptor to detect its ligand. For example, directly labeling cytokine receptor, fusing onto it markers for secondary labeling, e.g., FLAG or other epitope tags, etc., will allow detection of receptor. This can be histological, as an affinity method for biochemical purification, or labeling or selection in an expression cloning approach.
  • a two-hybrid selection system may also be applied making appropriate constructs with the available cytokine receptor sequences. See, e.g., Fields and Song (1989) Nature 340:245-
  • Human sequences related to cytokine receptors were identified from genomic sequence database using, e.g., the BLAST server (Altschul, et al. (1994) Nature Genet. 6:119-129). Standard analysis programs may be used to evaluate structure, e.g., PHD (Rost and Sander (1994) Proteins 19:55-72) and DSC (King and Sternberg (1996) Protein Set. 5:2298-2310). Standard comparison software includes, e.g., Altschul, et al. (1990)
  • PCR primers derived from the sequences are used to probe a human cDNA library. Sequences may be derived, e.g., from Tables 1-5, preferably those adjacent the ends of sequences.
  • Full length cDNAs for primate, rodent, or other species DCRS8 are cloned, e.g., by DNA hybridization screening of ⁇ gtlO phage. PCR reactions are conducted using T. aquaticus Taqplus DNA polymerase (Stratagene) under appropriate conditions. Extending partial length cDNA clones is typically routine. Chromosome spreads are prepared. In situ hybridization is performed on chromosome preparations obtained from phytohemagglutinin-stimulated human lymphocytes cultured for 72 h. 5-bromodeoxyuridine was added for the final seven hours of culture (60 ⁇ g/ml of medium), to ensure a posthybridization chromosomal banding of good quality.
  • a PCR fragment, amplified with the help of primers, is cloned into an appropriate vector.
  • the vector is labeled by nick-translation with -1H.
  • the radiolabeled probe is hybridized to metaphase spreads at final concentration of 200 ng/ml of hybridization solution as described, e.g., in Mattei, et al. (1985) Hum. Genet. 69:327-331.
  • chromosome spreads are first stained with buffered Giemsa solution and metaphase photographed. R-banding is then performed by the fluorochrome-photolysis-Giemsa (FPG) method and metaphases rephotographed before analysis.
  • FPG fluorochrome-photolysis-Giemsa
  • mRNA Human multiple tissue (Cat# 1, 2) and cancer cell line blots (Cat# 7757-1), containing approximately 2 ⁇ g of poly(A) + RNA per lane, are purchased from Clontech (Palo Alto, CA). Probes are radiolabeled with [ ⁇ -32p] dATP, e.g., using the Amersham Rediprime random primer labeling kit (RPN1633). Prehybridization and hybridizations are performed, e.g., at 65° C in 0.5 M Na2HP ⁇ 4, 7% SDS, 0.5 M EDTA (pH 8.0). High stringency washes are conducted, e.g., at 65° C with two initial washes in 2 x SSC, 0.1%
  • RT-PCR is used on an appropriate mRNA sample selected for the presence of message to produce a cDNA, e.g., a sample which expresses the gene.
  • Full length clones may be isolated by hybridization of cDNA libraries from appropriate tissues pre-selected by PCR signal. Northern blots can be performed.
  • DCRS DCRS Message for genes encoding DCRS will be assayed by appropriate technology, e.g., PCR, irnmunoassay, hybridization, or otherwise. Tissue and organ cDNA preparations are available, e.g., from Clontech, Mountain View, CA. Identification of sources of natural expression are useful, as described. And the identification of functional receptor subunit pairings will allow for prediction of what cells express the combination of receptor subunits which will result in a physiological responsiveness to each of the cytokine ligands.
  • appropriate technology e.g., PCR, irnmunoassay, hybridization, or otherwise.
  • Tissue and organ cDNA preparations are available, e.g., from Clontech, Mountain View, CA. Identification of sources of natural expression are useful, as described. And the identification of functional receptor subunit pairings will allow for prediction of what cells express the combination of receptor subunits which will result in a physiological responsiveness to each of the cytokine ligands
  • DNA 5 ⁇ g
  • DNA 5 ⁇ g
  • a primary amplified cDNA library was digested with appropriate restriction enzymes to release the inserts, run on a 1% agarose gel and transferred to a nylon membrane (Schleicher and Schuell, Keene, NH).
  • Samples for mouse mRNA isolation may include: resting mouse fibroblastic L cell line (C200); BrafiER (Braf fusion to estrogen receptor) transfected cells, control (C201); T cells, TH1 polarized (Mell4 bright, CD4+ cells from spleen, polarized for 7 days with IFN- ⁇ and anti IL-4; T200); T cells, TH2 polarized (Mell4 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN- ⁇ ; T201); T cells, highly TH1 polarized (see Openshaw, et al. (1995) J. Exp. Med.
  • T cells 1357-1367; activated with anti- CD3 for 2, 6, 16 h pooled; T202); T cells, highly TH2 polarized (see Openshaw, et al. (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 16 h pooled; T203); CD44- CD25+ pre T cells, sorted from thymus (T204); TH1 T cell clone Dl.l, resting for 3 weeks after last stimulation with antigen (T205); TH1 T cell clone Dl.l, 10 ⁇ g/ml ConA stimulated 15 h (T206); TH2 T cell clone CDC35, resting for 3 weeks after last stimulation with antigen (T207); TH2 T cell clone CDC35, 10 ⁇ g/ml ConA stimulated 15 h (T208); Mell4+ naive T cells from spleen, resting (T209); Mell4+ T
  • spleen see Kuhn, et al. (1991) Cell 75:263-274; X201); total adult spleen, normal (O201); total spleen, rag-1 (O207); IL-10 K.O. Peyer's patches (O202); total Peyer's patches, normal (0210); IL-10 K.O. mesenteric lymph nodes (X203); total mesenteric lymph nodes, normal (0211); IL-10 K.O. colon (X203); total colon, normal (0212); NOD mouse pancreas (see Makino, et al.
  • Samples for human mRNA isolation may include, e.g.: peripheral blood mononuclear cells (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell, THO clone Mot 72, resting (T102); T cell, THO clone Mot 72, activated with anti- CD28 and anti-CD3 for 3, 6, 12 h pooled (T103); T cell, THO clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); T cell, TH1 clone HY06, resting (T107); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T108); T cell, TH1 clone HY06, anergic treated with specific peptid
  • T109 T cell, TH2 clone HY935, resting (TI 10); T cell, TH2 clone HY935, activated with anti-CD28 and anti-CD3 for 2, 7, 12 h pooled (Till); T cells CD4+CD45RO- T cells polarized 27 days in anti-CD28, IL-4, and anti IFN- ⁇ , TH2 polarized, activated with anti-CD3 and anti-CD28 4 h (TI 16); T cell tumor lines Jurkat and Hut78, resting (TI 17); T cell clones, pooled AD130.2, Tc783.12, Tc783.13,
  • GS1 (XI 03); lung fibroblast sarcoma line MRC5, activated with PMA and ionomycin for 1, 6 h pooled (ClOl); kidney epithelial carcinoma cell line CHA, activated with PMA and ionomycin for 1, 6 h pooled (C102); kidney fetal 28 wk male (O100); lung fetal 28 wk male (O101); liver fetal 28 wk male (O102); heart fetal 28 wk male (O103); brain fetal 28 wk male (O104); gallbladder fetal 28 wk male (O106); small intestine fetal 28 wk male (O107); adipose tissue fetal 28 wk male (O108); ovary fetal 25 wk female (O109); uterus fetal 25 wk female (0110); testes fetal 28 wk male (0111); spleen fetal 28 wk male (0112
  • TaqMan quantitative PCR techniques have shown the DCRS6, in both mouse and human, to be expressed on T cells, including thymocytes and CD4+ naive and differentiated (hDCRS6 is also expressed on dendritic cells), in gastrointestinal tissue, including stomach, intestine, colon and associated lymphoid tissue, e.g., Peyer's patches and mesenteric lymph nodes, and upregulated in inflammatory models of bowel disease, e.g., IL-10 KO mice.
  • the hDCRS7 was detected in both resting and activated dendritic cells, epithelial cells, and mucosal tissues, including GI and reproductive tracts.
  • IL-17RA is highly expressed in innate immune myeloid cells including dendritic cells and monocytes. Expression is also detected in T-cell libraries.
  • T cell T cell, TH1 clone HY06, anergic 19.23 monocytes, LPS, gIFN, IL-10, 4+16 hr 19.3 spleen fetal 19.51 testes fetal 19.7
  • T cell gd clones resting 20.27 ovary fetal 20.45
  • T cell THO clone Mot 72, anergic 21.87 small intestine fetal 22.01
  • T cell THO clone Mot 72, activated 23.3 monocytes, LPS, gIFN, anti-IL-10, 4+16 hr 23.39
  • T cell THO clone Mot 72, activated 23.56 Pneumocystic carnii pneumonia lung sample 24.05
  • DCRS6_H is expressed in innate immune myeloid cells including dendritic cells and monocytes. Expression is also detected in T-cell libraries. These data demonstrate the receptor is expressed in immune cell types and may be regulated by activation conditions.
  • T cell T cell, TH2 clone HY935, resting 20.48 kidney epithelial carcinoma cell line CHA, 21.07 activated
  • T cell T cell, TH1 clone HY06, anergic 21.14 normal human colon 21.29
  • T cell THO clone Mot 72, anergic 23.2 ovary fetal 23.51 normal human thyroid 24.03 small intestine fetal 24.13 testes fetal 24.82 epithelial cells, IL-lb activated 26.08 pool of three heavy smoker human lung 26.49 samples placenta 28 wk 26.56 normal w.t. monkey lung 28.65 peripheral blood mononuclear cells, 33.39 activated
  • DCRS7JH Primers specific for DCRS7JH were designed and used in Taqman quantative PCR against various human libraries.
  • DCRS7_H is expressed in innate immune myeloid cells including dendritic cells and monocytes. Expression is also detected in fetal libraries. These data demonstrate the receptor is expressed in immune cell types and may be regulated by activation conditions.
  • DC TNF/TGFb act CD34-der. 22.54 fetal brain 22.9
  • DCRS9JH Primers specific for DCRS9JH were designed and used in Taqman quantative PCR against various human libraries.
  • DCRS9_H is expressed T-cells, fetal lung, and resting monocytes. These data demonstrate the receptor is expressed in immune cell types and may be regulated by activation conditions.
  • Mot 72 activated 29.21 fetal testes 29.27 lung 080698-2 29.32
  • PBMC activated 31.82 inflammed tonsil 31.98 fetal brain 32.21
  • Various strategies are used to obtain species counte ⁇ arts of the DCRSs, preferably from other primates or rodents.
  • One method is by cross hybridization using closely related species DNA probes. It may be useful to go into evolutionarily similar species as intermediate steps.
  • Another method is by using specific PCR primers based on the identification of blocks of similarity or difference between genes, e.g., areas of highly conserved or nonconserved polypeptide or nucleotide sequence. Sequence database searches may identify species counte ⁇ arts.
  • An appropriate, e.g., GST, fusion construct is engineered for expression, e.g., in E. coli.
  • a mouse IGIF pGex plasmid is constructed and transformed into E. coli.
  • Freshly transformed cells are grown, e.g., in LB medium containing 50 ⁇ g/ml ampicillin and induced with IPTG (Sigma, St. Louis, MO). After overnight induction, the bacteria are harvested and the pellets containing the appropriate protein are isolated. The pellets are homogenized, e.g., in TE buffer (50 mM Tris-base pH 8.0, 10 mM EDTA and 2 mM pefabloc) in 2 liters.
  • TE buffer 50 mM Tris-base pH 8.0, 10 mM EDTA and 2 mM pefabloc
  • This material is passed through a microfluidizer (Microfluidics, Newton, MA) three times.
  • the fluidized supernatant is spun down on a Sorvall GS-3 rotor for 1 h at 13,000 rpm.
  • the resulting supernatant containing the cytokine receptor protein is filtered and passed over a glutathione-SEPHAROSE column equilibrated in 50 mM Tris-base pH 8.0.
  • Fractions containing the DCRS8-GST fusion protein are pooled and cleaved, e.g., with thrombin (Enzyme Research Laboratories, Inc., South Bend, IN).
  • the cleaved pool is then passed over a Q-SEPHAROSE column equilibrated in 50 mM Tris-base.
  • Fractions containing DCRS8 are pooled and diluted in cold distilled H2O, to lower the conductivity, and passed back over a fresh Q-Sepharose column, alone or in succession with an immunoaffinity antibody column.
  • Fractions containing the DCRS 8 protein are pooled, aliquoted, and stored in the -70° C freezer.
  • Balb/c mice are immunized intraperitoneally with recombinant forms of the protein, e.g., purified DCRS8 or stable transfected NIH-3T3 cells. Animals are boosted at appropriate time points with protein, with or without additional adjuvant, to further stimulate antibody production. Serum is collected, or hybridomas produced with harvested spleens. Alternatively, Balb/c mice are immunized with cells transformed with the gene or fragments thereof, either endogenous or exogenous cells, or with isolated membranes enriched for expression of the antigen. Serum is collected at the appropriate time, typically after numerous further administrations. Various gene therapy techniques may be useful, e.g., in producing protein in situ, for generating an immune response. Serum or antibody preparations may be cross-absorbed or immunoselected to prepare substantially purified antibodies of defined specificity and high affinity.
  • the protein e.g., purified DCRS8 or stable transfected NIH-3T3 cells. Animals are boosted at appropriate time points with protein,
  • Monoclonal antibodies may be made. For example, splenocytes are fused with an appropriate fusion partner and hybridomas are selected in growth medium by standard procedures. Hybridoma supernatants are screened for the presence of antibodies which bind to the DCRS8, e.g., by ELISA or other assay. Antibodies which specifically recognize specific DCRS8 embodiments may also be selected or prepared.
  • synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (ed. 1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989)
  • the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods.
  • Nucleic acids may also be introduced into cells in an animal to produce the antigen, which serves to elicit an immune response. See, e.g., Wang, et al. (1993) Proc. Nat'l. Acad. Sci. 90:4156-4160; Barry, et al. (1994)
  • DCRS8 or DCRS9 A portion of the appropriate gene is fused to an epitope tag, e.g., a FLAG tag, or to a two hybrid system construct. See, e.g., Fields and Song (1989) Nature 340:245-246.
  • the epitope tag may be used in an expression cloning procedure with detection with anti-FLAG antibodies to detect a binding partner, e.g., ligand for the respective cytokine receptor.
  • a binding partner e.g., ligand for the respective cytokine receptor.
  • the two hybrid system may also be used to isolate proteins which specifically bind to the receptor subunit.
  • Standard mutagenesis analysis is performed, e.g., by generating many different variants at determined positions, e.g., at the positions identified above, and evaluating biological activities of the variants. This may be performed to the extent of determining positions which modify activity, or to focus on specific positions to determine the residues which can be substituted to either retain, block, or modulate biological activity.
  • analysis of natural variants can indicate what positions tolerate natural mutations. This may result from populational analysis of variation among individuals, or across strains or species. Samples from selected individuals are analyzed, e.g., by PCR analysis and sequencing. This allows evaluation of population polymo ⁇ hisms.
  • a cytokine receptor can be used as a specific binding reagent to identify its binding partner, by taking advantage of its specificity of binding, much like an antibody would be used.
  • the binding receptor may be a heterodimer of receptor subunits; or may involve, e.g., a complex of the DCRS8 with another cytokine receptor subunit.
  • a binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods.
  • the binding composition is used to screen an expression library made from a cell line which expresses a binding partner, i.e., ligand, preferably membrane associated.
  • a binding partner i.e., ligand, preferably membrane associated.
  • Standard staining techniques are used to detect or sort surface expressed ligand, or surface expressing transformed cells are screened by panning. Screening of intracellular expression is performed by various staining or immunofluorescence procedures. See also
  • HBSS Hank's Buffered Saline Solution
  • PFAVglucose 4%> paraformaldehyde
  • the slides may be stored at -80 C after all liquid is removed.
  • 0.5 ml incubations are performed as follows. Add HBSS/saponin (0.1%) with 32 ⁇ l ml of 1 M NaN3 for 20 min. Cells are then washed with HBSS/saponin IX. Add appropriate DCRS8 or DCRS8/antibody complex to cells and incubate for 30 min. Wash cells twice with
  • HBSS/saponin If appropriate, add first antibody for 30 min. Add second antibody, e.g.,
  • Vector anti-mouse antibody at 1/200 dilution, and incubate for 30 min.
  • Prepare ELISA solution e.g., Vector Elite ABC horseradish peroxidase solution, and preincubate for 30 min.
  • Use e.g., 1 drop of solution A (avidin) and 1 drop solution B (biotin) per 2.5 ml
  • HBSS/saponin Wash cells twice with HBSS/saponin. Add ABC HRP solution and incubate for 30 min. Wash cells twice with HBSS, second wash for 2 min, which closes cells. Then add Vector diaminobenzoic acid (DAB) for 5 to 10 min. Use 2 drops of buffer plus 4 drops DAB plus 2 drops of H2O2 per 5 ml of glass distilled water. Carefully remove chamber and rinse slide in water. Air dry for a few minutes, then add 1 drop of Crystal Mount and a cover slip. Bake for 5 min at 85-90 C.
  • DAB Vector diaminobenzoic acid
  • receptor reagents are used to affinity purify or sort out cells expressing a putative ligand. See, e.g., Sambrook, et al. or Ausubel, et al.
  • Another strategy is to screen for a membrane bound receptor by panning.
  • the receptor cDNA is constructed as described above. Immobilization may be achieved by use of appropriate antibodies which recognize, e.g., a FLAG sequence of a DCRS 8 fusion construct, or by use of antibodies raised against the first antibodies. Recursive cycles of selection and amplification lead to enrichment of appropriate clones and eventual isolation of receptor expressing clones.
  • Phage expression libraries can be screened by mammalian DCRS 8. Appropriate label techniques, e.g., anti-FLAG antibodies, will allow specific labeling of appropriate clones.
  • DCRS receptors to specifically bind IL-17 family cytokines. Recombinant FLAG-hIL-17 family cytokines were used in binding experiments on Baf73 DCRS receptor transfected expressing recombinant IL-17R_H, DCRS6_H, DCRS7_H, DCRS8JH and DCRS9_H and analyzed by FACS.
  • IL-17 family member IL-74 to DCRS6 expressing Baf/3 cells. In additional experiments we have shown IL-17 specific binding to IL-17R_H,
  • DCRS7JH DCRS8_H.
  • Further experiments show IL-71 binding to DCRS8_Hu transfectants. These experiments demonstrate the sequence homology among IL-17 related cytokine receptors confers functional binding to IL-17 cytokines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des acides nucléiques codant pour des récepteurs de mammifères, par exemple, de primates ou de rongeurs, des protéines de récepteurs purifiées et des fragments de ces dernières. L'invention concerne également des anticorps polyclonaux et monoclonaux. Enfin, l'invention concerne des procédés d'utilisation des compositions à des fins diagnostiques et thérapeutiques.
PCT/US2001/016767 2000-05-24 2001-05-23 Proteines de recepteurs de mammiferes, reactifs et procedes apparentes WO2001090358A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001587152A JP2003534013A (ja) 2000-05-24 2001-05-23 哺乳動物レセプタータンパク質；関連試薬および方法
MXPA02011617A MXPA02011617A (es) 2000-05-24 2001-05-23 Proteinas de mamiferos receptoras, reactivosy metodos relacionados.
AU2001274920A AU2001274920A1 (en) 2000-05-24 2001-05-23 Mammalian receptor proteins; related reagents and methods
CA002410083A CA2410083A1 (fr) 2000-05-24 2001-05-23 Proteines de recepteurs de mammiferes, reactifs et procedes apparentes
EP01941579A EP1303604A2 (fr) 2000-05-24 2001-05-23 Proteines de recepteurs de mammiferes, reactifs et procedes apparentes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20686200P 2000-05-24 2000-05-24
US60/206,862 2000-05-24

Publications (2)

Publication Number Publication Date
WO2001090358A2 true WO2001090358A2 (fr) 2001-11-29
WO2001090358A3 WO2001090358A3 (fr) 2003-01-23

Family

ID=22768279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016767 WO2001090358A2 (fr) 2000-05-24 2001-05-23 Proteines de recepteurs de mammiferes, reactifs et procedes apparentes

Country Status (8)

Country Link
US (2) US20030092881A1 (fr)
EP (1) EP1303604A2 (fr)
JP (1) JP2003534013A (fr)
CN (1) CN1444652A (fr)
AU (1) AU2001274920A1 (fr)
CA (1) CA2410083A1 (fr)
MX (1) MXPA02011617A (fr)
WO (1) WO2001090358A2 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004519A2 (fr) * 2000-07-06 2002-01-17 Zymogenetics, Inc. Recepteur de cytokine murin
WO2002038764A2 (fr) * 2000-11-10 2002-05-16 The Regents Of The University Of California Proteine de type recepteur il-17, utilisation de celle-ci et modulation de l'activite catabolique des cytokines il-17 sur l'os et le cartilage
EP1529843A2 (fr) * 2000-08-11 2005-05-11 Eli Lilly & Company Protéines sécrétées et leurs utilisations
WO2005065711A2 (fr) * 2003-12-29 2005-07-21 Schering Corporation Proteines de recepteurs de mammiferes, reactifs et procedes associes
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
EP1897943A2 (fr) * 1999-12-23 2008-03-12 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US7473763B2 (en) 1999-12-23 2009-01-06 Genentech, Inc. Receptor for IL-17 homologous polypeptides and uses thereof
US7544482B2 (en) 2000-08-24 2009-06-09 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US7749500B2 (en) 1998-05-15 2010-07-06 Genentech, Inc. Antibodies to IL-17 polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
JP2010227106A (ja) * 2002-09-11 2010-10-14 Genentech Inc 免疫関連疾患の治療のための新規組成物と方法
US7842665B2 (en) 2005-09-28 2010-11-30 Zymogenetics, Inc. IL-17A and IL-17F antagonists
EP2383278A1 (fr) * 2002-07-08 2011-11-02 Genentech, Inc. Méthode pour déterminer B cellulaire maladies
US8268773B2 (en) 2004-06-10 2012-09-18 Zymogenetics, Inc. Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist
US20150158912A1 (en) * 2011-10-27 2015-06-11 The Cleveland Clinic Foundation Treatment of il-17 mediated disease by blocking sefir-sefir interactions
US9650437B2 (en) 2008-05-05 2017-05-16 Novimmune S.A. Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies
US10011654B2 (en) 2003-07-08 2018-07-03 Genentech, Inc. Antibodies directed to IL-17A/IL-17F heterodimers

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028256A1 (es) * 2000-03-16 2003-04-30 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
CA2584078A1 (fr) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Zcytor21, anticorps anti-zcytor21 et partenaires de liaison solubles ainsi que procedes de leur utilisation lors d'une inflammation
US20060147945A1 (en) * 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
DK1931697T3 (da) * 2005-09-28 2010-11-08 Zymogenetics Inc IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
AU2007300393B2 (en) * 2006-02-10 2012-05-31 Zymogenetics, Inc. Soluble IL-17RCx4 and methods of using in inflammation
BRPI1014544B8 (pt) 2009-05-05 2021-05-25 Novimmune Sa anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
EP2956157A4 (fr) * 2013-02-15 2017-03-01 Thomas Jefferson University Kit pour imagerie d'une tumeur
EP3160479A4 (fr) * 2014-06-30 2018-07-04 Academia Sinica Antagonistes de récepteur de l'interleukine-17 b (il-17rb) et son ligand il-17b pour le traitement du cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029408A1 (fr) * 1995-03-23 1996-09-26 Immunex Corporation Recepteur il-17
WO1999014240A1 (fr) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
WO1999055865A1 (fr) * 1998-04-29 1999-11-04 Genesis Research And Development Corporation Limited Polynucleotides isoles de cellules de la peau et leurs procedes d'utilisation
WO2001046420A2 (fr) * 1999-12-23 2001-06-28 Genentech, Inc. Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
WO2001068859A2 (fr) * 2000-03-16 2001-09-20 Amgen Inc. Molecules du type recepteur de l'interleukine 17 et leur utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150502A (en) * 1998-04-29 2000-11-21 Genesis Research & Development Corporation Limited Polypeptides expressed in skin cells
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029408A1 (fr) * 1995-03-23 1996-09-26 Immunex Corporation Recepteur il-17
WO1999014240A1 (fr) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
WO1999055865A1 (fr) * 1998-04-29 1999-11-04 Genesis Research And Development Corporation Limited Polynucleotides isoles de cellules de la peau et leurs procedes d'utilisation
WO2001046420A2 (fr) * 1999-12-23 2001-06-28 Genentech, Inc. Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
WO2001068859A2 (fr) * 2000-03-16 2001-09-20 Amgen Inc. Molecules du type recepteur de l'interleukine 17 et leur utilisation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [Online] EBI; 18 February 2000 (2000-02-18) BLOECKER ET AL.: "Homo sapiens mRNA; cDNA DKFZp434N1928" Database accession no. AL133097 XP002183453 *
DATABASE EMBL [Online] EBI; 21 October 1999 (1999-10-21) MARRA ET AL.: "ul91g04.y1 Sugano mouse kidney mkia Mus musculus cDNA clone IMAGE:2159478 5', mRNA sequence" Database accession no. AW107583 XP002209554 *
DATABASE EMBL [Online] EBI; 22 July 1999 (1999-07-22) NCI-CGAP: "ty30c03.x1 NCI_CGAP_UT2 Homo sapiens cDNA clone IMAGE:2280580 3' mRNA sequence" Database accession no. AI861981 XP002209553 *
FOSSIEZ F ET AL: "INTERLEUKIN-17" INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, LONDON, GB, vol. 16, no. 5/6, 1998, pages 541-551, XP000867763 ISSN: 0883-0185 *
SHI YANGGU ET AL: "A novel cytokine receptor-ligand pair: Identification, molecular characterization, and in vivo immunomodulatory activity." JOURNAL OF BIOLOGICAL CHEMISTRY (JBC PAPERS IN PRESS, DOI 10.1074/JBC.M910228199), vol. 275, no. 25, 3 April 2000 (2000-04-03), pages 19167-19176, XP002197927 ISSN: 0021-9258 *
TIAN E ET AL: "EVI27 ENCODES A NOVEL MEMBRANE PROTEIN WITH HOMOLOGY TO THE IL17 RECEPOR" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 19, no. 17, 20 April 2000 (2000-04-20), pages 2098-2109, XP008000240 ISSN: 0950-9232 *
YAO Z ET AL: "MOLECULAR CHARACTERIZATION OF THE HUMAN INTERLEUKIN (IL)-17 RECEPTOR" CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 9, no. 11, November 1997 (1997-11), pages 794-800, XP000867704 ISSN: 1043-4666 *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749500B2 (en) 1998-05-15 2010-07-06 Genentech, Inc. Antibodies to IL-17 polypeptides and therapeutic uses thereof
US8273703B2 (en) 1998-05-15 2012-09-25 Genentech, Inc. IL-17 receptor-like polypeptides and therapeutic uses thereof
US8075888B2 (en) 1998-05-15 2011-12-13 Genentech, Inc. Methods of treatment using antibodies to IL-17 homologous polypeptides
EP2290081A3 (fr) * 1999-12-23 2012-08-01 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US7473763B2 (en) 1999-12-23 2009-01-06 Genentech, Inc. Receptor for IL-17 homologous polypeptides and uses thereof
EP2258848A1 (fr) * 1999-12-23 2010-12-08 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US7491512B2 (en) 1999-12-23 2009-02-17 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
EP1897943A3 (fr) * 1999-12-23 2008-06-11 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1897946A3 (fr) * 1999-12-23 2008-05-28 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1897943A2 (fr) * 1999-12-23 2008-03-12 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1897946A2 (fr) * 1999-12-23 2008-03-12 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1897944A3 (fr) * 1999-12-23 2008-05-21 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US8034342B2 (en) 2000-01-11 2011-10-11 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7943738B2 (en) 2000-03-16 2011-05-17 Amgen Inc. IL-17 receptor like molecules and uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US8338132B2 (en) 2000-03-21 2012-12-25 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2002004519A3 (fr) * 2000-07-06 2002-09-26 Zymogenetics Inc Recepteur de cytokine murin
WO2002004519A2 (fr) * 2000-07-06 2002-01-17 Zymogenetics, Inc. Recepteur de cytokine murin
EP1529843A3 (fr) * 2000-08-11 2005-06-08 Eli Lilly & Company Protéines sécrétées et leurs utilisations
EP1529843A2 (fr) * 2000-08-11 2005-05-11 Eli Lilly & Company Protéines sécrétées et leurs utilisations
US7544482B2 (en) 2000-08-24 2009-06-09 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US8455217B2 (en) 2000-10-24 2013-06-04 Genentech, Inc. Nucleic acids encoding IL-17 homologous receptor-like polypeptides and therapeutic uses thereof
WO2002038764A2 (fr) * 2000-11-10 2002-05-16 The Regents Of The University Of California Proteine de type recepteur il-17, utilisation de celle-ci et modulation de l'activite catabolique des cytokines il-17 sur l'os et le cartilage
WO2002038764A3 (fr) * 2000-11-10 2003-07-10 Univ California Proteine de type recepteur il-17, utilisation de celle-ci et modulation de l'activite catabolique des cytokines il-17 sur l'os et le cartilage
EP2383278A1 (fr) * 2002-07-08 2011-11-02 Genentech, Inc. Méthode pour déterminer B cellulaire maladies
AU2010201437B9 (en) * 2002-09-11 2012-08-02 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2010201437B2 (en) * 2002-09-11 2012-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2010227106A (ja) * 2002-09-11 2010-10-14 Genentech Inc 免疫関連疾患の治療のための新規組成物と方法
US10011654B2 (en) 2003-07-08 2018-07-03 Genentech, Inc. Antibodies directed to IL-17A/IL-17F heterodimers
WO2005065711A2 (fr) * 2003-12-29 2005-07-21 Schering Corporation Proteines de recepteurs de mammiferes, reactifs et procedes associes
WO2005065711A3 (fr) * 2003-12-29 2005-09-01 Schering Corp Proteines de recepteurs de mammiferes, reactifs et procedes associes
US8268773B2 (en) 2004-06-10 2012-09-18 Zymogenetics, Inc. Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist
US7842665B2 (en) 2005-09-28 2010-11-30 Zymogenetics, Inc. IL-17A and IL-17F antagonists
US8084231B2 (en) 2007-03-28 2011-12-27 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins and related methods
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
US9650437B2 (en) 2008-05-05 2017-05-16 Novimmune S.A. Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies
US20150158912A1 (en) * 2011-10-27 2015-06-11 The Cleveland Clinic Foundation Treatment of il-17 mediated disease by blocking sefir-sefir interactions
US9611295B2 (en) 2011-10-27 2017-04-04 The Cleveland Clinic Foundation Treatment of IL-17 mediated disease by blocking SEFIR-SEFIR interactions

Also Published As

Publication number Publication date
CN1444652A (zh) 2003-09-24
US20050009145A1 (en) 2005-01-13
JP2003534013A (ja) 2003-11-18
AU2001274920A1 (en) 2001-12-03
EP1303604A2 (fr) 2003-04-23
CA2410083A1 (fr) 2001-11-29
MXPA02011617A (es) 2003-03-10
US20030092881A1 (en) 2003-05-15
WO2001090358A3 (fr) 2003-01-23

Similar Documents

Publication Publication Date Title
US7510853B2 (en) Nucleic acids encoding DCRS5
US20050009145A1 (en) Mammalian receptor proteins; related reagents and methods
WO2002020569A2 (fr) Genes mammaliens, reactifs et methodes associes
AU2001261351A1 (en) Mammalian receptor proteins; related reagents and methods
WO1999040195A1 (fr) Proteines de recepteurs de mammiferes; reactifs et procedes apparentes
CA2392109A1 (fr) Proteines de recepteurs mammaliens, reactifs et procedes s'y rapportant
EP1181366B2 (fr) Proteines de recepteur mammaliennes, reactifs et procedes y relatifs
WO1999046379A2 (fr) Proteines receptrices humaines; reactifs et procedes associes
US20110021412A1 (en) Human Receptor Proteins; Related Reagents and Methods
US20050106673A1 (en) Mammalian receptor proteins; related reagents and methods
US20040197306A1 (en) Mammalian receptor proteins; related reagents and methods
AU2007202362B2 (en) Mammalian receptor proteins; related reagents and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001941579

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2410083

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/011617

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018133274

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001941579

Country of ref document: EP